B
Bullisch
Bullisch · 25%STVN
$30.64
Szenariopreis
$19.490
-0.010 (-0.05%)Zum Schluss
Loading chart…
- Hoch
- 19.765
- Eröffnung
- 19.460
- Volumengewichteter Durchschnittskurs
- 19.50
- Volumen
- 403.47K
- Marktkap.
- 5.11B
- Tief
- 19.240
- Umsatz
- 7.87M
- EV/EBITDA, TTM
- 17.07
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
KI-Analyse of Stevanato Group SpA (STVN)
KaufenStevanato Group (STVN) is a good buy right now at $19.49, especially considering the recent earnings report showing a 7.9% year-over-year revenue growth and a gross margin improvement to 28.7%. The forward P/E ratio of 29.15 suggests the stock is reasonably valued given its growth potential. However, the main risk lies in the company’s execution risks around ramping new capacity, which could impact future performance.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Stevanato Group SpA (STVN) beträgt 29.15, verglichen mit dem 5-Jahres-Durchschnitt von 35.40.
Alphio-AI-Kursszenarien für STVN
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die STVN halten
Event-Zeitleiste
News
2.008-05NASDAQ.COMStevanato (STVN) Q2 2026 Earnings Call Transcript
9.508-04seekingalphaStevanato Group Reports Strong Q2 Earnings with Strategic Divestiture
8.508-04NewsfilterStevanato Group Divests California Subsidiary Balda C. Brewer, Inc.
- 8.507-30Newsfilter
Stevanato Group Secures European Approvals for New Injector Therapies
- 9.507-21Newsfilter
Stevanato Group to Release Q2 2026 Financial Results
STVN FAQ – beantwortet von Alphio AI
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
Stevanato Group (STVN) is a good buy right now at $19.49, especially considering the recent earnings report showing a 7.9% year-over-year revenue growth and a gross margin improvement to 28.7%. The forward P/E ratio of 29.15 suggests the stock is reasonably valued given its growth potential. However, the main risk lies in the company’s execution risks around ramping new capacity, which could impact future performance.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.